Visudyne verteporfin: Final Phase IV data

Data from the Asian Phase IV EVEREST trial in 61 patients showed that Visudyne alone and in combination with Lucentis ranibizumab met the primary endpoint of complete polyp regression at 6 months vs. Lucentis alone (71.4% and 77.8% vs. 28.6%, p=0.0037 and p=0.0018). At 6 months, Visudyne alone and in combination with Lucentis led to mean gains from baseline in BCVA score of 9.2 and 10.9 letters, respectively, vs. 7.5 letters for Visudyne alone. The differences in BCVA scores were not statistically significant, but QLT said the trial was not powered to detect statistical significance in visual acuity. All therapies were well tolerated. ...